CENTRAL DISTRICT, Hong Kong
- Sept. 29, 2020
-- The partnership will leverage extensive experience gained 1Globe Biomedical's research team related to the biology and culture expansion of T-cells with the focus on EBV-related cancer.
1Globe Biomedical will manufacture compliant T-cells to generate next-generation therapies to treat a wide-range of different cancer types will cell testing and initial clinical studies to be planned for early 2021.
1Globe Biomedical's Chief Medical Officer commented on the Korean partnership saying "1Globe Biomedical has grown rapidly over the last few years due to extensive and unrivaled cell therapy experience leveraged by our experienced research and medical team of scientists. Our Korean counterparts are also pioneers in this field and we feel that this partnership will be very fruitful in terms of treatments and developments."
A spokesperson from the Korean biomedical firm also commented on the partnership saying "It is a great pleasure to be working a company with the experience of 1Globe Biomedical. This partnership will provide us with an enormous opportunity to fast-track T-cell production and to test and manufacture safe and effective treatment to cancer patients. This collaboration with 1Globe Biomedical gives us an opportunity to translate our basic research on T cells into immunotherapies for cancer and infectious disease."
About Us - 1Globe Biomedical
1Globe Biomedical is a clinical stage biotechnology company pioneering the development of receptor T (1BioCARs™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of "off-the-shelf"
receptor T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.http://1globe-biomedical.com/about-us/history/index.html